Furthermore, the efficacy of chidamide in combination with PET regimens (CPET) has been evaluated in several clinical trials (18), further supporting the higher mutation frequency of TET2 and DNMT3A in AITL. This evidence concerns the gene DNMT3A and angioimmunoblastic T-cell lymphoma.